Haemonetics (NYSE:HAE) Stock Rating Upgraded by Baird R W

Haemonetics (NYSE:HAE - Get Free Report) was upgraded by investment analysts at Baird R W to a "strong-buy" rating in a report issued on Wednesday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. JMP Securities restated a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Robert W. Baird initiated coverage on shares of Haemonetics in a research note on Thursday. They issued an "outperform" rating and a $87.00 price objective on the stock. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Needham & Company LLC dropped their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Haemonetics currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.80.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $74.81 on Wednesday. Haemonetics has a 12 month low of $55.30 and a 12 month high of $94.99. The firm has a market capitalization of $3.59 billion, a P/E ratio of 22.60, a P/E/G ratio of 1.19 and a beta of 0.36. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The company's fifty day moving average price is $67.47 and its 200 day moving average price is $68.34.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. During the same quarter in the previous year, the firm earned $0.90 earnings per share. The business's revenue was down 3.5% compared to the same quarter last year. As a group, sell-side analysts predict that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its stake in shares of Haemonetics by 1.0% during the 4th quarter. Principal Financial Group Inc. now owns 156,734 shares of the medical instruments supplier's stock worth $12,238,000 after buying an additional 1,475 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the period. Fisher Asset Management LLC raised its position in Haemonetics by 3.2% in the fourth quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock worth $55,575,000 after acquiring an additional 22,265 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Haemonetics by 1.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 551,193 shares of the medical instruments supplier's stock valued at $43,037,000 after acquiring an additional 8,477 shares during the period. Finally, Arizona State Retirement System lifted its holdings in Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after acquiring an additional 181 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.